Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis

Jean Yves Reginster, Cyrus Cooper, Marc Hochberg, Jean Pierre Pelletier, René Rizzoli, John Kanis, Eric Abadie, Emmanuel Maheu, Maria Luisa Brandi, Jean Pierre Devogelaer, Jaime Branco, Gabriel Herrero-Beaumont, Pieter D'Hooghe, Olivier Bruyère

Research output: Contribution to journalReview article

14 Citations (Scopus)
18 Downloads (Pure)

Abstract

Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthritis, the American College of Rheumatology (ACR) guidelines (concerning also hip and hand osteoarthritis) and the algorithm recommendations by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). This is particularly evident for the drug class of symptomatic slow-acting drugs in osteoarthritis. In this paper, we highlight these differences and try to understand where they derive from, proposing an evidence-based interpretation.

Original languageEnglish
Pages (from-to)1041-1045
Number of pages5
JournalCurrent Medical Research and Opinion
Volume31
Issue number5
DOIs
Publication statusPublished - 1 May 2015

Keywords

  • Chondroitin
  • Glucosamine
  • Hyaluronic acid
  • Osteoarthritis
  • Symptomatic slow-acting drugs in osteoarthritis

Fingerprint Dive into the research topics of 'Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis'. Together they form a unique fingerprint.

Cite this